Trial document



drksid header

  DRKS00019106

Trial Description

start of 1:1-Block title

Title

A Confirmatory, Prospective, Open-label, Single-arm, Reader-blinded Multi-centre Phase 3 Study to Assess the Diagnostic Accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and Unenhanced MRI in Reference to Histopathology in Newly-diagnosed Prostate Cancer (PCA) Patients, Scheduled for Radical Prostatectomy (RP) With Extended Pelvic Lymph Node Dissection (ePLND).

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

SPL-01-001

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

https://ferrotran.com/

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The aim of this study is to assess if Ferumoxtran-10 is suitable contrast agent for magnetic resonance imaging (MRI) to identify small lymph nodes metastasis in the pelvic region. This study is conducted to evaluate the diagnostic accuracy and safety of Ferumoxtran-10. The study is intended for patients suffering from prostate cancer with an intermediate to high risk for metastasis and which are scheduled for a prostatcetomy with extended lymph node removal.
Ferumoxtran-10 consists of ultra small iron-particles and is sensitive and specific for the detection of lymph node metastases. A solution of Ferumoxtran-10 is administered via injection into the vein and will be taken up in healthy tissue but not in cancer tissue.
In the imaging process the Ferumoxtran-10 particles which are distributed to the whole body can be made visible. Healthy tissue appears darkened because the Ferumoxtran-10 was takes up whereas the cancer tissue stayes lighter.
This method allows the detection of very small lymph nodes (2 mm) in comparison to normally used scans which can identify metastases from a size of 7-8 mm.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This will be a confirmatory, prospective, open-label, single-arm, reader-blinded, multi-centre phase 3 study to assess the diagnostic accuracy and safety of Ferrotran®-enhanced MRI in comparison to unenhanced MRI in the detection of pelvic lymph node metastases in newly-diagnosed patients with prostate cancer and an intermediate to high risk for lymph node metastases, based on the D'Amico criteria.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

No

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00019106
  •   2020/02/26
  •   2020/02/10
  •   no
  •   Approved
  •   19/0223-EK 11, Ethik-Kommission des Landes Berlin
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2018-004310-18 
  •   NCT04261777  (ClinicalTrials.gov)
  •   SPL-01-001  (Saving Patients' Lives Medical B.V.)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C61 -  Malignant neoplasm of prostate
  •   metastasised lymph nodes in the pelvic region
  •   high risk prostate cancer
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   After signing the consent form, inclusion and exclusion criteria are checked and screening examinations (e.g. blood pressure, pulse, 12-channel electrocardiogram (ECG) and normal MRI) are performed.
    On the day of treatment (day 0), a physical examination, vital signs an weight again assessed before administration of Ferumoxtran-10 (0.13 mL/kg). The contrast medium is administered via slow infusion over a period of 30 minutes. During this time and and for the following 30 min (60 minutes in total), the patient is closely monitored by the study staff to detect any possible allergic or infusion-related reactions. Another physical examination as well as vital signs and laboratory paramateres will be performed four hours after the end of the infusion.
    The next day (day 1) the Ferumoxtran-10 enhanced MRI scan is performed.
    Seven days after the Ferumoxtran-10 infusion, another physical examination and assessment of vital signs are performed as well as blood and urine samples are taken.
    Days 7 to 42: During this period, the planned prostatectomy (removal of the prostate) with extended removal of the lymph nodes in the pelvic area is performed. Prior to this surgery (on the same day or one day before) the same examinations are performed as on day 7.
    About 8 weeks after the surgery, blood and urine samples are assessed again and a normal MRT is also performed.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Diagnostic
  •   Single (group)
  •   III
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Lymph node metastases will be detected by MRI scan (Ferumoxtran-10-enhanced and unenhanced).
True positive fraction and false positive fraction of identified tumour tissue in pelvic lymph nodes will be analysed by histopathology as established reference method. Based on these parameters the sensitivity and specificity will be evaluated.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Number and regions of lymph node metastases present in the follow-up MRI in comparison to pre-surgery MRI (unenhanced and Ferrotran®-enhanced)
- Frequency of occurrence and severity of abnormal findings in safety investigations (physical examination, vital signs, 12-lead ECG, clinical laboratory, concomitant medication, adverse events)
- Percentage of subjects for whom the patient management plan would be changed based on the Ferrotran®-enhanced MRI

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
  •   Switzerland
  •   Netherlands
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
  • Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • Medical Center 
  • Medical Center 
  • University Medical Center 
  • Medical Center 
  • University Medical Center 
  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2020/05/27
  •   200
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Male
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. Voluntarily given and written informed consent.
2. Male ≥18 years of age.
3. Histologically newly-confirmed adenocarcinoma of the prostate.
4. Medium to high risk for lymph node metastasis, defined by either:
a. PSA ≥10 ng/mL or
b. Gleason-Score ≥7 or
c. Stage cT2b or cT2c or T3 or T4
5. Patients scheduled for radical prostatectomy (RP) with extended lymph node dissection (ePLND) between Day 7 and Day 42 after Ferrotran®-enhanced MRI.
6. Consent to practice contraception until end of study, including female partners of childbearing potential. Effective contraceptive measures include hormonal oral, injected or implanted female contraceptives, male condom, vaginal diaphragm, cervical cap, intrauterine device.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. Any contraindication to MRI, as per standard criteria.
2. Any radiation therapyor systemic antiproliferative (chemo-, immuno, or hormonal) therapy for prostate cancer (Lupron, Taxotere, Casodex, Eulexin, Zoladex, etc.) prior to screening and until after post-surgery FUP MRI.
3. Known hypersensitivity to Ferrotran® or its components such as dextran.
4. Known hypersensitivity to other parenteral iron products.
5. Acute allergy, including drug allergies and allergic asthma.
6. Evidence of iron overload or disturbances in the utilisation of iron (e.g., haemochromatosis, haemosiderosis, chronic haemolytic anaemia with frequent blood transfusions).
7. Presence of liver dysfunction.
8. Any other investigational medicinal product within 30 days prior to receiving study medication until end of study visit.
9. Simultaneous participation in any other clinical trial.
10. Abnormal safety laboratory values at screening or baseline that are assessed by the principal investigator as clinically relevant.
11. Patients not able to declare meaningful informed consent on their own (e.g. with legal guardian for mental disorders), or other vulnerable patients (e.g. under arrest).
12. Patients with acute SARS-CoV-2 infection

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Saving Patients' Lives Medical B.V. (SPL Medical)
    • Transistorweg 5
    • 6534  AT Nijmegen
    • Netherlands
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • ABX - CRO advanced pharmaceutical services Forschungsgesellschaft mbH
    • Blasewitzer Str. 78-80
    • 01307  Dresden
    • Germany
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Saving Patients' Lives Medical B.V.(SPL Medical)
    • Mr.  Michael  Berghahn 
    • Transistorweg 5
    • 6534  AT Nijmegen
    • Netherlands
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • ABX-CRO Forschungsgeschellschaft
    • Studienteam  SPL-01-001 
    • Hindenburgdamm 30
    • 12203  Berlin
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Saving Patients' Lives Medical B.V.(SPL Medical)
    • Transistorweg 5
    • 6534  AT Nijmegen
    • Netherlands
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
  •   [---]*
  •   [---]*
  •   [---]*
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications


* This entry means the parameter is not applicable or has not been set.